[Estrogens and breast cancer]

After a short bibliographical revision on the estrogen action in the genesis of mammarian cancer, it can be accepted that they can only act under the analyzed circumstances. For these reasons, it is advised that the Substitutive Hormonal Therapy (SHT) during menopause with estrogens should not be extended for more than five years, nor should it be given to women over 60 years of age. SHT combined with progesterone protects against endometrial cancer, but increases the relative risk of mammarian cancer. It should not be prescribed for hysterectomized patients who should follow previous advices. Both types of SHT should be avoided by hypertensive women treated with calcium blockers and women have familiar records of mamarian cancer.